At the time when the current Board was constituted, Accrol faced multiple challenges, some of which had been self-inflicted. From the outset, the priority of the Board has been to:

Dan Wright, Executive Chairman of Accrol, said: "Over the last four years, Accrol has been transformed as an organisation to one that currently supplies c.21.5% of the UK market's tissue volumes and has considerable further capacity. Our state-of-the-art businesses are in an incredibly strong position to benefit in a private label market, which is growing rapidly and significantly. Our customer base is strong and varied and the ability to pass-on cost increases swiftly has been evidenced in the Group's Half Year Results, also announced today. We look forward with increased confidence, having clearly identified where we can grow the business."On a fully comparable basis, the land and building costs in the location that we have chosen are expected to be c.50% lower than originally announced.

Here, BusinessLive lifts the lid of the AIM-listed group which has experienced rapid growth over recent years. History This could lead to lead to rapid margin improvement in H1 24 and could be reflected in the FY24 outlook due soon.Reverse the significant historic under-investment in terms of capital, physical capacity and people; Our vision is to deliver the best possible value to the UK consumer on essential everyday tissue products. We are shaking up traditional tissue brands by delivering the quality the consumer wants for the price they want to pay. In the 2023 final results EBITDA market expectations for 2024 were raised from 19.5 to 20.5m. Two months later they have been raised again to "at least 21m"